Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer

被引：0

作者：

O'Malley, David M.

Monk, Bradley J.

Lim, Myong Cheol

Pradera, Jose Fuentes

Buscema, Joseph

Wilson, Michelle K.

De Vivo, Rocco

Herzog, Thomas J.

Zagouri, Flora

Oza, Amit M.

Mikheeva, Olga N.

Diaz, John Paul

Lisyanskaya, Alla Sergeevna

Morris, Robert

Bruchim, Ilan

Craib, Marcia

Connor, Christy

Shih, Danny

Fujiwara, Keiichi

Kristeleit, Rebecca

机构：

[1] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH USA

[2] Creighton Univ, Univ Arizona, GOG Fdn, Coll Med,Sch Med, Phoenix, AZ USA

[3] Natl Canc Ctr Korea, Gynecol Oncol, Goyang Si, Gyeonggi Do, South Korea

[4] Hosp Univ Virgen Valme, Seville, Spain

[5] Arizona Oncol Associates, Tucson, AZ USA

[6] Auckland City Hosp, Dept Canc & Blood, Auckland, New Zealand

[7] Osped San Bortolo, Dept Med Oncol, Vicenza, Italy

[8] Univ Cincinnati, Cincinnati, OH USA

[9] Alexandra Hosp, Dept Clin Therapeut, Athens, Greece

[10] Princess Margaret Hosp Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[11] Ltd Liabil Co MedPomosch, St Petersburg, Russia

[12] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA

[13] St Petersburg State Budget Healthcare Inst, City Clin Oncol Dispensary, St Petersburg, Russia

[14] Wayne State Univ, Karmanos Canc Inst, Div Gynecol Oncol, Dept Oncol,Sch Med, Detroit, MI USA

[15] Rappaport Fac Med, Hillel Yaffe Med Ctr, Hadera, Israel

[16] Pharma&, Stat Programming, New York, NY USA

[17] Pharma&, Clin Operat, New York, NY USA

[18] Saitama Med Univ Int Med Ctr, Dept Gynecol Oncol, Hidaka, Saitama, Japan

[19] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5554

引用

页数：1

共 50 条

[31] Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial in Japan
Nakaoka, Yoshikazu
Isobe, Mitsuaki
Takei, Syuji
Tanaka, Yoshiya
Ishii, Tomonori
Yokota, Shumpei
Nomura, Akira
Yoshida, Seitaro
Nishimoto, Norihiro
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[32] Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Banerjee, Susana
Moore, Kathleen N.
Colombo, Nicoletta
Scambia, Giovanni
Kim, Byoung-Gie
Oaknin, Ana
Friedlander, Michael
Lisyanskaya, Alla
Floquet, Anne
Leary, Alexandra
Sonke, Gabe S.
Gourley, Charlie
Oza, Amit
Gonzalez-Martin, Antonio
Aghajanian, Carol
Bradley, William H.
Holmes, Eileen
Lowe, Elizabeth S.
DiSilvestro, Paul
LANCET ONCOLOGY, 2021, 22 (12): : 1721 - 1731
[33] ENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.
Mirza, M.
Berek, J. S.
Vergote, I.
Wenham, R. M.
Del Campo, J. M.
Oza, A. M.
Mahner, S.
Monk, B. J.
Fabbro, M.
Ledermann, J. A.
Marth, C.
Bruchim, I.
Katsaros, D.
Lorusso, D.
Malander, S.
Dorum, A.
Agarwal, S.
Martell, R. E.
Matulonis, U.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 33 - 34
[34] Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial
McDonald, C.
Wu, S.
Gulati, S.
Komaki, H.
Ruiz-Garcia, M.
Kostera-Pruszczyk, A.
Vlodavets, D.
Chae, J.
Jong, Y.
Karachunski, P.
Statland, J.
Lorentzos, M.
Penematsa, V
Chou, C.
Lin, M.
Werner, C.
Trifillis, P.
Gordon, G.
Klein, M.
NEUROMUSCULAR DISORDERS, 2022, 32
[35] Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
McDonald, Craig M.
Wu, Shiwen
Gulati, Sheffali
Komaki, Hirofumi
Escobar, Rosa E.
Kostera-Pruszczyk, Anna
Vlodavets, Dmitry
Chae, Jong-Hee
Jong, Yuh-Jyh
Karachunski, Peter
Statland, Jeffrey
Lorentzos, Michelle
Penematsa, Vinay
Chou, Connie
Lin, Min
Werner, Christian
Trifillis, Panayiota
Gordon, Gregory
Koladicz, Karyn
Mastrandrea, Nicholas
Klein, Matthew
NEUROLOGY, 2023, 100 (17)
[36] Dapoxetine for the Treatment of Premature Ejaculation: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial in 22 Countries
Buvat, Jacques
Tesfaye, Fisseha
Rothman, Margaret
Rivas, David A.
Giuliano, Francois
EUROPEAN UROLOGY, 2009, 55 (04) : 957 - 968
[37] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Takeshima, Takao
Sakai, Fumihiko
Hirata, Koichi
Imai, Noboru
Matsumori, Yasuhiko
Yoshida, Ryuji
Peng, Cheng
Cheng, Sunfa
Mikol, Daniel D.
HEADACHE, 2021, 61 (06): : 927 - 935
[38] Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Gonzalez-Martin, Antonio
Pothuri, Bhavana
Vergote, Ignace
Graybill, Whitney
Lorusso, Domenica
McCormick, Colleen C.
Freyer, Gilles
Backes, Floor
Heitz, Florian
Redondo, Andres
Moore, Richard G.
Vulsteke, Christof
O'Cearbhaill, Roisin E.
Malinowska, Izabela A.
Shtessel, Luda
Compton, Natalie
Mirza, Mansoor R.
Monk, Bradley J.
EUROPEAN JOURNAL OF CANCER, 2023, 189
[39] EFFICACY AND SAFETY OF ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS: RESULTS FROM THE ELATIVE™ DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
Bowlus, Christopher L.
Kowdley, Kris V.
Levy, Cynthia
Akarca, Ulus
Alvares-Da-Silva, Mario Reis
Andreone, Pietro
Arrese, Marco
Corpechot, Christophe
Francque, Sven
Heneghan, Michael A.
Invernizzi, Pietro
Jones, David
Kruger, Frederik C.
Lawitz, Eric
Mayo, Marlyn J.
Shiffman, Mitchell L.
Swain, Mark G.
Valera, Jose Miguel
Vargas, Victor
Vierling, John M.
Villamil, Alejandra
Addy, Carol
Dietrich, Julie
Germain, Jean-Michel
Mazain, Sarah
Rafailovic, Dragutin
Tadde, Bachirou
Miller, Benjamin
Shu, Jianfen
Zein, Claudia O.
Schattenberg, Jorn M.
HEPATOLOGY, 2024, 79 (02) : E40 - E42
[40] Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary
Gonzalez-Martin, Antonio
Pothuri, Bhavana
Vergote, Ignace
Graybill, Whitney
Lorusso, Domenica
McCormick, Colleen C.
Freyer, Gilles
Backes, Floor
Heitz, Florian
Redondo, Andres
Moore, Richard G.
Vulsteke, Christof
O'Cearbhaill, Roisin E.
Malinowska, Izabela A.
Shtessel, Luda
Compton, Natalie
Mirza, Mansoor R.
Monk, Bradley J.
FUTURE ONCOLOGY, 2024, 20 (22) : 1531 - 1544

← 1 2 3 4 5 →